Product Description
Mechanisms of Action:
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Oral, Subcutaneous, Sublingual
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Bulgaria | Canada | Czech | Denmark | Estonia | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Luxembourg | Malta | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Kingdom | United States
Approved Indications: Conjunctivitis | Conjunctivitis, Allergic | Other | Rhinitis | Rhinitis, Allergic
Known Adverse Events: None
Company: Allergy Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Bulgaria, Czech Republic, Germany, Latvia, Lithuania, Poland, Romania, Slovakia, Spain, United Kingdom
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Asthma, Allergic|Conjunctivitis, Allergic|Dust mite Hypersensitivity|Environmental Hypersensitivity|Rhinitis, Allergic|Rhinitis, Allergic, Seasonal
Phase 2: Grass Pollen Hypersensitivity
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2025-520581-22-00 |
PRO-RCT-GRAM-2025-01 | P2 |
Withdrawn |
Conjunctivitis, Allergic |
2026-03-31 |
|||
NCT04502966 |
GRADUATE | P2 |
Completed |
Conjunctivitis, Allergic|Grass Pollen Hypersensitivity|Environmental Hypersensitivity|Rhinitis, Allergic, Seasonal |
2025-02-20 |
12% |
2025-04-15 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2023-508520-36-00 |
PQGrass308 | P3 |
Recruiting |
Rhinitis, Allergic, Seasonal|Conjunctivitis, Allergic |
2032-10-31 |
2025-05-02 |
Treatments |
|
2023-504942-75-01 |
PM/0059 | P3 |
Active, not recruiting |
Dust mite Hypersensitivity|Conjunctivitis, Allergic|Asthma, Allergic|Rhinitis, Allergic|Environmental Hypersensitivity |
2026-08-31 |
2025-05-02 |
Treatments |
|
2024-517521-25-00 |
SC-3G2A | P3 |
Not yet recruiting |
Asthma, Allergic|Conjunctivitis, Allergic|Rhinitis, Allergic |
2027-12-10 |
|||
2024-517524-18-00 |
SL-3Q2A | P3 |
Not yet recruiting |
Asthma, Allergic|Conjunctivitis, Allergic|Rhinitis, Allergic |
2027-11-24 |
|||
2024-511383-88-00 |
SC-3C2A | P3 |
Active, not recruiting |
Asthma, Allergic|Conjunctivitis, Allergic|Rhinitis, Allergic |
2026-09-30 |
2025-05-02 |
Treatments |
|
2023-505880-35-00 |
2023-505880-35-00 | P3 |
Completed |
Rhinitis, Allergic|Conjunctivitis, Allergic|Asthma, Allergic |
2024-11-07 |
2025-05-02 |
Treatments |
|
2023-505567-37-00 |
2023-505567-37-00 | P3 |
Completed |
Rhinitis, Allergic|Asthma, Allergic|Conjunctivitis, Allergic |
2024-10-11 |
2025-05-02 |
Treatments |
|
2019-001517-16 |
2019-001517-16 | P3 |
Completed |
Rhinitis, Allergic, Seasonal|Conjunctivitis, Allergic |
2023-11-01 |
2025-05-06 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/18/2025 |
News Article |
Pollen Seasons are Longer and More Intense, Affecting Millions |
|
05/31/2024 |
News Article |
Stallergenes Greer Showcases New Data for Food and Respiratory Immunotherapy at 2024 EAACI Congress |
|
10/25/2023 |
News Article |
Revolo Biotherapeutics Announces Data from Study of '1104 in Atopic Adults |
|
10/10/2023 |
News Article |
Allergy Treatment Market is expected to reach USD 31.63 billion by 2029 |